NCT03260881View on ClinicalTrials.gov

Liraglutide Effects on Epicardial Fat Inflammatory Genes

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions
Type2 DiabetesCoronary Artery Disease
Interventions
DRUG

Liraglutide Pen Injector [Victoza]

Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).

DRUG

matching liraglutide-placebo pre-filled pens

Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).

Trial Locations (1)

33136

University of Miami, Miami

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

University of Miami

OTHER